| DxS is a personalised medicine company providing molecular diagnostics to aid doctors and drug companies in selecting therapies for patients. DxS offers products, technology and services to the healthcare industry to enable the delivery of safe and effective medicines. Working predominantly in the field of cancer, DxS have a range of companion diagnostic and research kits that detect mutations in oncogenes associated with cancer drug response. The TheraScreen® range of CE-marked diagnostic products includes kits that detect mutations in the EGFR and K-RAS genes. Tumour mutation products are available for research use for EGFR, RAS, RAF, BCR-ABL and other genes that show a correlation between patient mutation status and drug response. DxS’ real-time PCR technology Scorpions®, known for its speed and sensitivity, underpins the products and services offered by DxS. This class-leading technology is also available for licence to diagnostic companies, for research, applied and other applications. DxS also provide a genetic analysis service to support clinical development. DxS is ISO 13485: 2003 and ISO 9001: 2000 certified for the manufacture of medical devices and the provision of genetic analysis services and technologies to the healthcare industry. DxS is an established company operating in Manchester’s Technology Quarter within the UK. | | 
| |
| |